↓ Skip to main content

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

Overview of attention for article published in Journal of Hematology & Oncology, May 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#47 of 1,349)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
5 news outlets
twitter
29 X users

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Published in
Journal of Hematology & Oncology, May 2023
DOI 10.1186/s13045-023-01444-2
Pubmed ID
Authors

Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Farhad Ravandi, Elias Jabbour

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 8%
Other 2 8%
Student > Postgraduate 2 8%
Researcher 2 8%
Student > Doctoral Student 1 4%
Other 2 8%
Unknown 13 54%
Readers by discipline Count As %
Medicine and Dentistry 5 21%
Unspecified 2 8%
Immunology and Microbiology 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Unknown 15 63%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2024.
All research outputs
#855,738
of 26,601,477 outputs
Outputs from Journal of Hematology & Oncology
#47
of 1,349 outputs
Outputs of similar age
#18,269
of 419,263 outputs
Outputs of similar age from Journal of Hematology & Oncology
#3
of 28 outputs
Altmetric has tracked 26,601,477 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,349 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,263 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.